After nearly two years of turnover in the FDA's top ranks, the agency named Mikhail and Davis as permanent leaders of CBER and CDER. Analysts say the appointments should help ease concerns about future turmoil and provide stability for the industry.

The FDA placed a partial hold on opakalim, affecting a study that some analysts believe is necessary to support potential approval. The halt was announced just weeks after Biohaven sold off rights to the therapy.

Plump joined Takeda during a turbulent period and pushed the company to work more closely with young biotechs. CEO Julie Kim credited him with leaving a lasting foundation for the company's research and development operations.

RA Capital has already participated in four biotech financings in September, demonstrating continued appetite for investment. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand. The trend has created a booming business on Wall Street for biotech companies seeking public market access.

The new company is advancing a medicine from China's Harbour BioMed that it believes can address the weaknesses of drugs aimed at CTLA-4. CTLA-4 is a popular but tricky cancer immunotherapy target.

AbbVie is eyeing an extended use case for Qulipta following positive Phase III results in menstrual migraine. The win could expand the commercial opportunity for the migraine prevention therapy.

BioMarin painted a picture of wider efficacy for its dwarfism drug Voxzogo following a Phase III win. The results support expanded use of the therapy in treating the condition.

Remission rates observed in a Phase 2 trial of dabogratinib fell short of Wall Street's expectations. However, some analysts believe the company should see better results in late-stage testing.

At ERS 2026, Sanofi reported that lunsekimig met Phase IIb goals in asthma treatment. The positive results set the stage for Phase III development of the investigational therapy.

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. The move comes as the company faces financial pressures and explores strategic alternatives.

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions. The new biotech startup is backed by Eli Lilly.

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines. The barriers represent significant obstacles to bringing these promising therapies to market.